

BY E-MAIL

August 2, 2023

BSE Ltd. Phiroze Jeejeebhoy Towers 27 th Floor, Dalal Street Mumbai 400 023 E-mail: corp.relations@bseindia.com	The National Stock Exchange of India Ltd. Exchange Plaza, 5 th Flr, Plot # C/1 G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051. E-mail : takeover@nse.co.in
--	--

Dear Sir,

Re: Declaration under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith disclosure for acquisition by us of 2,35,01,440 equity shares of Rs. 2/- each of M/s. Unichem Laboratories Limited (506690 on BSE; UNICHEMLAB on NSE) constituting about 33.38% voting rights of the said Company.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For and on behalf Ipca Laboratories Limited



Harish P. Kamath
Company Secretary



Encl: a/a

Cc: Unichem Laboratories Limited
Unichem Bhavan
Prabhat Estate, Off S.V.Road, Jogeshwari (West),
Mumbai – 400 102
E-mail id : pradeep.bhandari@unichemlabs.com
shares@unichemlabs.com

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part A – Details of Acquisition

Name of the Target Company (TC)	Unichem Laboratories Limited (506690 on BSE; UNICHEMLAB on NSE)		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer	Ipca Laboratories Limited		
Whether the acquirer belongs to Promoter / Promoter Group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	BSE Ltd. (BSE); and The National Stock Exchange of India Ltd. (NSE)		
Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t total diluted share / voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a. Shares carrying voting rights	Nil	Nil	Nil
b. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
c. Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e. Total (a+b+c+d)	Nil	Nil	Nil
Details of Acquisition			
a. Shares carrying voting rights acquired	2,35,01,440	33.38%	33.38%
b. VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+/-d)	2,35,01,440	33.38%	33.38%




Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

After the acquisition, holding of			
a. Shares carrying voting rights	2,35,01,440	33.38%	33.38%
b. VRs otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
f. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
d. Total (a+b+c+d)	2,35,01,440	33.38%	33.38%
Mode of acquisition (eg. Open market / public issue/rights issue/preferential allotment/inter-se transfer etc.)	Through Block Deal Mechanism of The National Stock Exchange of India Ltd. (NSE)		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Not Applicable		
Date of acquisition of shares or date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	2 nd August, 2023		
Equity share capital/total voting capital of the TC before the said acquisition	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%
Total diluted share/voting capital of the TC after the said acquisition (considering balance outstanding convertible warrants)	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%




ipca Laboratories Ltd.

www.ipca.com


125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837



Signature of the acquirer / Authorised Signatory:

For Ipca Laboratories Ltd.

Harish P. Kamath
Company Secretary



Place: Mumbai

Date: 2nd August, 2023

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837